Form 4: Evolent Health Director Springstubb Reports Stock Transactions

Brendan B. Springstubb, a director at Evolent Health, Inc., reported the acquisition of shares and restricted stock units.

Summary

• On March 3, 2025, Brendan B. Springstubb, a director of Evolent Health, Inc., acquired 6,842 shares of Class A Common Stock as restricted stock units.
• These restricted stock units were granted under the company's 2015 Omnibus Incentive Compensation Plan.
• The shares vest on the earlier of March 3, 2026, or the date of the company's 2025 annual meeting, contingent upon continued service.
• On March 4, 2025, Springstubb purchased 5,000 shares of Class A Common Stock at a price of $8.75 per share.
• Following these transactions, Springstubb beneficially owns 11,842 shares of Class A Common Stock.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It's a routine disclosure of stock transactions by a company director. The purchase of shares could be seen as a slightly positive signal.

Positives

• A director's increased stake in the company can be seen as a positive signal.

Industry Context

Form 4 filings are standard disclosures required by the SEC to ensure transparency in insider trading activities.

Stakeholder Impact

• The transactions could have a minor positive impact on shareholder confidence.

Key Dates